Please login to the form below

Not currently logged in
Email:
Password:

Chronic idiopathic constipation

This page shows the latest Chronic idiopathic constipation news and features for those working in and with pharma, biotech and healthcare.

Shire bags US approval for constipation drug Motegrity

Shire bags US approval for constipation drug Motegrity

Approval is boost as Takeda takeover nears completion. Shire has the US approval it needs for Motegrity, a drug for chronic idiopathic constipation (CIC) that will compete with drugs like

Latest news

  • Immunology keeps Shire figures solid as Takeda takeover nears Immunology keeps Shire figures solid as Takeda takeover nears

    HAE, prucalopride (SHP555) for chronic idiopathic constipation, and calaspargase pegol (SHP663) for the treatment of acute lymphoblastic leukaemia (ALL).

  • Mallinckrodt pays $1.2bn for Sucampo Pharma Mallinckrodt pays $1.2bn for Sucampo Pharma

    As 2017 drew to a close, Mallinckrodt signed a deal to buy Sucampo Pharma of the US - and its constipation drug Amitizia - for $1.2bn. ... Amitizia is the prize asset in the deal, with FDA approvals in hand for three indications - chronic idiopathic

  • FDA approves Synergy's constipation drug Trulance FDA approves Synergy's constipation drug Trulance

    Synergy Pharma is celebrating after the FDA approved Trulance, its drug for the treatment of chronic idiopathic constipation (CIC) in adults. ... There are around 42 million people in the US who suffer from constipation, according to the National

  • AZ and Ironwood to file IBS drug linaclotide in China next year AZ and Ironwood to file IBS drug linaclotide in China next year

    A phase III trial of linaclotide in IBS with constipation (IBS-C) - conducted in China - showed that the drug improved symptoms such as abdominal pain and discomfort, bloating and straining whilst ... Linaclotide is a guanylate cyclase‐C agonist that

  • Lilly’s Efient and Sucampo's Amitiza win NICE backing Lilly’s Efient and Sucampo's Amitiza win NICE backing

    NICE, which provides healthcare recommendations to the NHS, issued new guidance on the use of Sucampo Pharma Europe's Amitiza (lubiprostone) for adults with chronic idiopathic constipation and updated its view ... Chronic idiopathic constipation can be

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics